Protalix BioTherapeutics, Inc. (PLX)

NYSEAMERICAN: PLX · USD

$2.61

+0.05 (+1.9%)· Recorded snapshot

Market cap	210.3M
Revenue (ttm)	80.6M
Net income (ttm)	18.9M
EPS (ttm)	$0.24
Shares out	80.6M
P/E (trailing)	11.0x
Volume	289,039.165
Beta	-0.02

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 80.6M
Net income (ttm): 18.9M
EPS (ttm): $0.24
P/E (trailing): 11.0x
Market cap: 210.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E11

P25 n/aP50 n/aP75 n/a

ROE31.2

P25 n/aP50 n/aP75 n/a

ROIC58.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PLX indicators

Market & fundamental data

Available fields

252

Groups with data

Currency

USD

Showing 252 of 252 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001006281
Company name	Protalix BioTherapeutics, Inc.
Country	United States
Country code	US
CUSIP number	74365A309
Earnings date	2026-11-10
Earnings time	bmo
Employees	226
Employees change	13
Employees growth	6.1%
Enterprise value	$178.8M
Exchange	NYSEAMERICAN
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1993
In index	RUSSELL2000
Industry	Biotechnology
IPO date	1998-05-15
Is primary listing	Yes
Is SPAC	No
ISIN number	US74365A3095
Last 10-K release date	2026-03-18
Last earnings date	2026-08-12
Last refreshed	2026-11-04
Last stock split date	2019-12-20
Last stock split type	Reverse
Market cap	$210.3M
Market cap category	Micro-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$2.61
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-11-03
Symbol	PLX
U.S. state	New Jersey
Website	https://www.protalix.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (3Y)	23.5x
Earnings yield	9.06%
EV/Earnings	9.44x
EV/EBIT	7.68x
EV/EBITDA	7.19x
EV/FCF	23.32x
EV/Sales	2.22x
FCF / EV yield	4.29%
FCF yield	3.65%
Forward EV/Sales	2.92x
Forward P/S	3.44x
Graham number	2.1713
Graham upside	-16.81%
Lynch fair value	$5.91
Lynch upside	126.47%
P/(FCF - SBC) ratio	38.89x
P/(OCF - SBC) ratio	27.44x
P/B ratio	2.95x
P/E ratio	11.04x
P/FCF ratio	27.42x
P/OCF ratio	21.19x
P/S ratio	2.61x
Price / tangible book value	2.95x
Price/EBITDA ratio	8.46x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	28.89%
EBITDA margin	30.84%
Effective tax rate	19.26%
FCF margin	9.51%
Gross margin	45.77%
Operating margin	28.89%
Pretax margin	29.1%
Profit margin	23.5%
Profit per employee	$83,827
Profitable quarters	2
Revenue per employee	$356,721
ROA	15.42%
ROA (5Y)	-4.52%
ROCE	29.5%
ROE	31.23%
ROIC	58.24%
ROIC (5Y)	-36.63%
SBC / revenue	2.8%
Tax / revenue	5.61%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	205.32%
EPS growth (Q)	2,241.1%
EPS growth (QoQ)	-78.54%
EPS growth 10Y	-26.28%
EPS growth 3Y	32.09%
EPS growth years	0
Gross profit growth	58.66%
Gross profit growth (Q)	23.97%
Gross profit growth 3Y	-8.87%
Gross profit growth 5Y	2.31%
Net income growth	201.91%
Net income growth (Q)	2,203.05%
Net income growth (QoQ)	-79.38%
Net income growth 3Y	28.63%
Net income growth quarters	2
Net income growth years	0
Operating income growth	183.1%
Operating income growth (Q)	298.63%
Operating income growth 3Y	23.58%
Revenue growth	30.14%
Revenue growth (Q)	27.07%
Revenue growth (QoQ)	-41.05%
Revenue growth 10Y	35.78%
Revenue growth 3Y	6.12%
Revenue growth 5Y	10.91%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.3M
Depreciation and amortization	$1.6M
EBIT	$23.3M
EBITDA	$24.9M
EPS	$0.24
FCF per share	$0.10
Financing cash flow	$296,000
Free cash flow	$7.7M
Free cash flow minus SBC	$5.4M
Gross profit	$36.9M
Income taxes	$4.5M
Investing cash flow	$-1M
Net cash flow	$9.5M
Net income	$18.9M
Operating cash flow minus SBC	$7.7M
Operating income	$23.3M
Revenue	$80.6M
Stock-based compensation	$2.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.03
Book value per share	$0.89
Debt / EBITDA	0.34
Debt / equity	0.13
Debt / FCF	1.2
Interest coverage	18.97
Long-term assets	$18.1M
Long-term liabilities	$7.5M
Net cash (debt)	$31.4M
Net cash / market cap	14.95%
Net cash growth	12.12%
Net debt / EBITDA	-1.27
Net debt / equity	-0.44
Net debt / FCF	-4.1
Piotroski F-Score	6
Property, plant and equipment	$13.6M
Shareholders' equity	$71.4M
Tangible book value	$71.4M
Tangible book value per share	$0.89
Total assets	$110.3M
Total cash	$40.7M
Total debt	$9.2M
Total liabilities	$38.9M
WACC	4.43%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.85
Current assets	$92.2M
Current liabilities	$31.4M
Current ratio	2.94
Inventory turnover	1.64
Net working capital	$21.8M
Quick ratio	1.82
Working capital	$60.8M
Working capital turnover	1.58

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	2.61%
Dividend yield	0%
Shareholder yield	2.61%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-41.99%
10Y return CAGR	-5.3%
10Y total return	-41.99%
150-day SMA	$2.36
15Y price change	-95.86%
15Y return CAGR	-19.13%
15Y total return	-95.86%
1D price change	1.95%
1M price change	-3.69%
1M total return	-3.69%
1W price change	3.16%
1W total return	3.16%
1Y price change	10.13%
1Y return CAGR	10.13%
1Y total return	10.13%
20-day SMA	$2.63
200-day SMA	$2.42
3M price change	10.13%
3M total return	10.13%
3Y price change	54.44%
3Y return CAGR	15.59%
3Y total return	54.44%
50-day SMA	$2.65
50-day SMA vs 200-day SMA	50over200
52-week high	$3.19
52-week high date	2026-02-23
52-week low	$1.65
52-week low date	2025-12-03
5Y price change	130.97%
5Y return CAGR	18.23%
5Y total return	130.97%
6M price change	23.11%
6M total return	23.11%
All-time high	$484.00
All-time high date	2007-08-22
All-time low	$0.70
All-time low date	2022-02-24
Average true range (ATR)	$0.10
Average volume	726K
Beta (1Y)	1.26
Beta (2Y)	0.89
Beta (5Y)	-0.02
Change from 52-week high	-18.18%
Change from 52-week low	58.18%
Change from all-time high	-99.46%
Change from all-time low	272.86%
Change from open	1.56%
Day's gap	0.39%
Dollar volume	$754,392
High price	$2.61
Low price	$2.52
Monthly RSI	56.65
Open price	$2.57
Position in 52-week range	100%
Premarket change	0.83%
Premarket close	$2.61
Premarket price	$2.63
Premarket volume	5.3K
Previous close	$2.56
Price vs 150-day SMA	10.64%
Price vs 20-day SMA	-0.61%
Price vs 200-day SMA	7.9%
Price vs 50-day SMA	-1.58%
Relative volume	0.4
RSI	49.36
Sharpe ratio	0.38
Sharpe ratio (3Y)	0.59
Sharpe ratio (5Y)	0.53
Sortino ratio	0.65
Sortino ratio (3Y)	0.91
Sortino ratio (5Y)	0.87
Volume	289K
Weekly RSI	55.6
YTD price change	45%
YTD total return	45%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	77.4M
Float percentage	96.12%
Shares change (QoQ)	-0.59%
Shares change (YoY)	-2.61%
Shares held by insiders	3.88%
Shares held by institutions	25.18%
Shares outstanding	80.6M
Short % of float	4.53%
Short % of shares	4.35%
Short ratio	4 days

Deeper analysis on PLX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PLX report

Is a complete PLX research report available?

No complete published report is available for Protalix BioTherapeutics, Inc. (PLX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Protalix BioTherapeutics, Inc. (PLX)

Price

Financial snapshot

Fair-value bridge

Latest news · PLX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PLX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PLX

Frequently asked questions